Corticosteroid and Long ‐Acting ß‐Agonist Therapy Reduces Epithelial Goblet Cell Metaplasia

Conclusion and Clinical RelevanceCorticosteroid treatment inhibits IL‐13‐induced GCM of the airways in asthma, possibly through its effects on SPDEF and FOXa2 regulation of mucin gene expression. These effects are modestly augmented by the addition of a long‐acting ß‐agonist. As we found evidence for drug treatment counter‐acting the effects of IL‐13 on the epithelium, we conclude that further exploration into the mechanisms by which corticosteroids and long‐acting β2‐adrenergic agonists confer protection against pathologic airway changes is warranted.This article is protected by copyright. All rights reserved.

Source: Clinical and Experimental Allergy - August 22, 2017 Category: Allergy & Immunology Authors: M.E. Lachowicz ‐Scroggins, W.E. Finkbeiner, E.D. Gordon, S. Yuan, L. Zlock, N.R. Bhakta, P.G. Woodruff, J.V. Fahy, H.A. Boushey Tags: Original Article ‐Asthma and Rhinitis Source Type: research